3Stadler BM, Miescher S, Horn M, et al. Allergic manifestationsas theres ults of a conditional autoimmune response [J]. Int Arch Allcrgy Immunol, 2001, 12,4(1-3): 411-413.
1[1]Greaves MW. Chronic urticaria[J]. N Engl J Med, 1995, 332(26):1767-1772.
2[2]O' Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life[J] . Br J Dermatol, 1997, 136(2):197-201.
3[3]Grattan CE, Wallington TB, Warin RP, et al. A serological mediator in chronic idiopathic urticaria-a clinical , immunological and histological evaluation[J]. Br J Dermatol, 1986, 114(5): 583-590.
4[4]Grattan CE, Francis DM, Hide M, et al. Detection of circulating histamine releasing autoantibodies with function properties of anti-IgE in chronic urticaria[J]. Clin Exp Allergy, 1991, 21 (6):695-704.
5[5]Hide M, Francis DM, Grattan CE, et al. Autoantibodies against the high-affinity IgE receptor as a cause for histamine release in chronic urticaria[J]. N Engl J Med, 1993, 328(22): 1599-1604.
6[6]Niimi N, Francis DM, Kermani F , et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria[J]. J Invest Dermatol, 1996, 106(5): 1001-1006.
7[7]Tong LJ, Balakrishnan G, Kochan JP, et al. Assessment of autoimmunity in patients with chronic urticaria[J] . J Allergy Clin Immunol, 1997, 99(4): 461-465.
8[8]Fiebiger E , Maurer D, Holub H, et al. Serum IgG autoantibodies directed against the alpha-chain of FcepsilonR: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria and pathogenetic factor for a distinct subset of chronic urticaria patients/[J]. J Clin Invest, 1995, 96(6): 2606-2612.
9[9]Fiebiger E, Hammersehmid F, Stingl G, et al. Anti- FcepsilonR autoantibodies in autoimmune-mediated disorder. Identification of a structure-function relationship[J] . J Clin Invest, 1998, 101 (1):243-251.
10[10]O' Donnell BF, O' Neill CM, Francis DM, et al. Human leucocyte antigen class Ⅱ associations in chronic idiopathic urticaria[J] . Br J Dermatol, 1999, 140(5): 853-858.
